OasisLMS

This educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence in Accredited Continuing Education by members of the Continuing Medical Education Committee. As an accredited provider, AASLD must collect information from all planners, faculty and others involved in the planning and control of continuing medical education (CME) activities to disclose all financial relationships with ineligible companies during the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the content.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to mitigate conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PLANNERS:

Robert Gish, MD, FAASLD
Scientific Consultant/Advisor: Intercept, Ipsen, Janssen, JBS Science, Kinnate Bio, Merck, Mirum, Precision BioSciences, Pfizer, Seres Therapeutics, Topography Health, Tune Therapeutics, Venatorx, Virion, Fujifilm/Wako, Quest, AbbVie, AstraZeneca, BlueJay Therapeutics, Brii Bio, EIT Pharma, Genlantis, Gerson Lehrman Group, Gilead Sciences, GlaxoSmithKline, HHHbio, Helio, HepQuant, Intercept, Ipsen, Madrigal, Mirum, Precision Bio, Prodigy, Topography Health, Tune , Virion
DSMB: Syneos Health
Consulting for Equity: Genlantis, HepQuant, HepaTx, Virion
Leadership in a Related Board: Genlantis, Gilead, HepaTX, HepQuant, Intercept, Prodigy;
Speakers' Bureau: Gilead Sciences Inc., Intercept, Ipsen Biopharmaceuticals, Madrigal, Mallinckrodt, Mirum

Min Kim
Nothing to Disclose

REVIEWERS: 

Andrew Keaveny, MD, FRCPI, FAASLD
Property Rights: UpToDate
Grant/Research Support: HepQuant, Biovie, Inc., Gabriel House of Care, Regeneron, River to Reno
Consultant: BioVie, Mallinckrodt Medical